These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2543344)

  • 41. [Design of Novel Carboxamides of Eremomycin and Vancomycin with 4- or 3-Amino Methyl Phenyl Boric Acid and Their Investigation].
    Bychkova EN; Korolev AM; Olsufyeva EN; Mirchink EP; Isakova EB
    Antibiot Khimioter; 2015; 60(9-10):7-11. PubMed ID: 27141632
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.
    Poulakou G; Giamarellou H
    Expert Opin Investig Drugs; 2008 Feb; 17(2):225-43. PubMed ID: 18230056
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pursuit of next-generation glycopeptides: a journey with vancomycin.
    Acharya Y; Dhanda G; Sarkar P; Haldar J
    Chem Commun (Camb); 2022 Feb; 58(12):1881-1897. PubMed ID: 35043130
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aminoalkylamides of Eremomycin Exhibit an Improved Antibacterial Activity.
    Moiseenko EI; Erdei R; Grammatikova NE; Mirchink EP; Isakova EB; Pereverzeva ER; Batta G; Shchekotikhin AE
    Pharmaceuticals (Basel); 2021 Apr; 14(4):. PubMed ID: 33921612
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008.
    Arhin FF; Moeck G; Draghi DC; Pillar CM; Sahm DF
    Int J Antimicrob Agents; 2010 Nov; 36(5):474-6. PubMed ID: 20846829
    [No Abstract]   [Full Text] [Related]  

  • 46. Novel ether derivatives of mannopeptimycin glycopeptide antibiotic.
    Sum PE; How D; Torres N; Petersen PJ; Lenoy EB; Weiss WJ; Mansour TS
    Bioorg Med Chem Lett; 2003 Mar; 13(6):1151-5. PubMed ID: 12643932
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Study of the activity of a new glycopeptide antibiotic eremomycin combined with tobramycin against Staphylococci in vitro].
    Iakushkina IV; Malkova IV; Prozorova IN
    Antibiot Khimioter; 1988 May; 33(5):342-5. PubMed ID: 3415389
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Recent trend and development of novel antimicrobial agents for MRSA infections].
    Nishino T
    Nihon Rinsho; 1992 May; 50(5):1066-74. PubMed ID: 1324332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.
    Asseray N; Jacqueline C; Le Mabecque V; Batard E; Bugnon D; Potel G; Caillon J
    Antimicrob Agents Chemother; 2005 Feb; 49(2):857-9. PubMed ID: 15673789
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A new series of glycopeptide antibiotics incorporating a squaric acid moiety. Synthesis, structural and antibacterial studies.
    Sztaricskai F; Batta G; Herczegh P; Balázs A; Jeko J; Roth E; Szabó PT; Kardos S; Rozgonyi F; Boda Z
    J Antibiot (Tokyo); 2006 Sep; 59(9):564-82. PubMed ID: 17136889
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis and antibacterial activity of N4-mono alkyl derivatives of novel glycopeptide LYV07ww01.
    Shao C; Zhou W; Zhang S; Wei W; Ruan L; Jin Y; Sun X; Huang Y
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6732-8. PubMed ID: 21978682
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vancomycin revisited: a reappraisal of clinical use.
    Cunha BA
    Crit Care Clin; 2008 Apr; 24(2):393-420, x-xi. PubMed ID: 18361953
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MM 45289, a potent glycopeptide antibiotic which interacts weakly with diacetyl-L-lysyl-D-alanyl-D-alanine.
    Good VM; Gwynn MN; Knowles DJ
    J Antibiot (Tokyo); 1990 May; 43(5):550-5. PubMed ID: 2113517
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glycopeptide antibiotics and development of inhibitors to overcome vancomycin resistance.
    Gao Y
    Nat Prod Rep; 2002 Feb; 19(1):100-7. PubMed ID: 11902437
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Surface mediated cooperative interactions of drugs enhance mechanical forces for antibiotic action.
    Ndieyira JW; Bailey J; Patil SB; Vögtli M; Cooper MA; Abell C; McKendry RA; Aeppli G
    Sci Rep; 2017 Feb; 7():41206. PubMed ID: 28155918
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of infection with Streptococcus bovis and Aspergillus sp. in irradiated mice after glycopeptide therapy.
    Brook I; Tom SP; Ledney GD
    J Antimicrob Chemother; 1993 Nov; 32(5):705-13. PubMed ID: 8125835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Janthinocins A, B and C, novel peptide lactone antibiotics produced by Janthinobacterium lividum. I. Taxonomy, fermentation, isolation, physico-chemical and biological characterization.
    O'Sullivan J; McCullough J; Johnson JH; Bonner DP; Clark JC; Dean L; Trejo WH
    J Antibiot (Tokyo); 1990 Aug; 43(8):913-9. PubMed ID: 2211359
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Experimental study of histamine-liberating properties of eremomycin].
    Filippos'iants ST; Shevniuk LA
    Antibiot Khimioter; 1989 Mar; 34(3):209-12. PubMed ID: 2473716
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Calculation of concentrations of equilibrium components in an in vitro activity test of vancomycin antibiotics and the possible mode of action.
    Yan H; Cheng X; He B
    Biophys Chem; 1998 Aug; 74(2):107-15. PubMed ID: 9760722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.